XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 01, 2024
Sep. 30, 2022
Mar. 31, 2023
Jul. 31, 2020
Mar. 31, 2024
Sep. 30, 2023
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2020
Preferred stock, shares issued (in shares)         0     0  
Acquired IPR&D expense   $ 3,000              
Quarterly fee $ 600       $ 1,300        
Delivery fee         200        
Completion fee         200        
Exercise fee         $ 1,000        
Accrued Upfront Fee                 $ 200
Royalty Based on Net Sales of Licensed Products, Percentage         1.00%        
Royalty expense         $ 0        
Research and Development [Member]                  
Quarterly fee         600   $ 1,300    
Research Development And Regulatory Milestone                  
Potential milestone payment         18,000        
Adimab Assignment Agreement [Member]                  
Milestone payment         $ 11,100     $ 11,100  
Adimab Assignment Agreement [Member] | Maximum [Member]                  
Potential milestone payment       $ 24,600          
Royalty percentage of sublicense consideration         55.00%        
Adimab Assignment Agreement [Member] | Minimum [Member]                  
Royalty percentage of sublicense consideration         45.00%        
Adimab Assignment Agreement [Member] | Research and Development [Member]                  
Recognized expense         $ 0   0    
Adimab Assignment Agreement [Member] | Acquired In Process Research And Development Expense [Member]                  
Milestone payment     $ 400   0 $ 3,200 400    
Adimab Assignment Agreement [Member] | First Product [Member]                  
Potential milestone payment       16,500          
Adimab Assignment Agreement [Member] | Second Product [Member]                  
Potential milestone payment       $ 8,100          
Adimab Collaboration Agreement [Member]                  
Expenses         0   200    
Adimab Collaboration Agreement [Member] | Research and Development [Member]                  
Quarterly fee         600   1,300    
Adimab Collaboration Agreement [Member] | Acquired In Process Research And Development Expense [Member]                  
Exercise fee         0   0    
Adimab Platform Transfer Agreement [Member] | Research Development And Regulatory Milestone                  
Potential milestone payment         9,500        
Cell Line License Agreement [Member]                  
Acquired IPR&D expense         $ 0   $ 400